Fred E. Cohen's most recent trade in Caredx Inc was a trade of 12,103 Common Stock done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 12,103 | 155,265 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,450 | 11,450 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 8,000 | 57,453 (0%) | 0% | 0 | Common Stock | |
| Kyverna Therapeutics Inc. | Fred E. Cohen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 65,351 | 65,351 | - | - | Stock Option (right to buy) | |
| Kyverna Therapeutics Inc. | Fred E. Cohen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 16,634 | 16,634 | - | 0 | Common Stock | |
| UroGen Pharma Ltd | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 16,048 | 16,048 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 16,048 | 16,048 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 10,570 | 143,162 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 49,453 (0%) | 0% | 0 | Common Stock | |
| Progyny Inc | Fred E. Cohen | Director | 23 May 2024 | 25,070 | 25,070 | - | - | Stock Option (Right to Buy) | ||
| Progyny Inc | Fred E. Cohen | Director | 23 May 2024 | 6,176 | 22,693 (0%) | 0% | 0 | Common Stock | ||
| Kyverna Therapeutics Inc. | Fred E. Cohen | Director, Ten Percent Owner | 12 Feb 2024 | 8,830,901 | 0 | - | - | Series A-2 Redeemable Convertible Preferred Stock | ||
| Kyverna Therapeutics Inc. | Fred E. Cohen | Director, Ten Percent Owner | 12 Feb 2024 | 7,356,162 | 0 | - | - | Series B Redeemable Convertible Preferred Stock | ||
| Kyverna Therapeutics Inc. | Fred E. Cohen | Director, Ten Percent Owner | 12 Feb 2024 | 4,523,924 | 4,523,924 | - | - | Common Stock | ||
| Kyverna Therapeutics Inc. | Fred E. Cohen | Director, Ten Percent Owner | 12 Feb 2024 | 4,401,771 | 0 | - | - | Series A-1 Redeemable Convertible Preferred Stock | ||
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 29,136 | 29,136 | - | - | Common Stock | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 18,844 | 132,592 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,473 | 6,473 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,425 | 41,716 (0%) | 0% | 0 | Common Stock | |
| Progyny Inc | Fred E. Cohen | Director | 24 May 2023 | 18,350 | 18,350 | - | - | Stock Option (Right to Buy) | ||
| Progyny Inc | Fred E. Cohen | Director | 24 May 2023 | 4,385 | 16,517 (0%) | 0% | 0 | Common Stock | ||
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 1,062 | 113,748 (0%) | 0% | 0 | Common Stock | |
| Progyny Inc | Fred E. Cohen | Director | 24 Oct 2022 | 15,660 | 15,660 | - | - | Stock Option (Right to Buy) | ||
| Progyny Inc | Fred E. Cohen | Director | 24 Oct 2022 | 3,480 | 12,132 (0%) | 0% | 0 | Common Stock | ||
| Progyny Inc | Fred E. Cohen | Director | 24 Oct 2022 | 1,460 | 1,460 | - | - | Stock Option (Right to Buy) | ||
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2022 | 803 | 112,686 (0%) | 0% | 0 | Common Stock | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,606 | 7,606 | - | - | Common Stock | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 4,863 | 111,883 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 37,291 (0%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Progyny Inc | Fred E. Cohen | Director | 24 Oct 2021 | 15,831 | 15,831 | - | - | Stock Option (right to buy) | ||
| Progyny Inc | Fred E. Cohen | Director | 24 Oct 2021 | 2,652 | 8,652 (0%) | 0% | 0 | Common Stock | ||
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 1,812 | 1,812 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 1,127 | 107,020 (0%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.78 per share. | 20 Jan 2021 | 20,000 | 30,000 (0%) | 0% | 13.8 | 275,600 | Common Stock |
| Intellia Therapeutics Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 20,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 06 Jan 2021 | 15,000 | 105,893 (0%) | 0% | 14.7 | 221,100 | Common Stock |
| Progyny Inc | Fred E. Cohen | Director | 24 Oct 2020 | 1,845 | 1,845 | - | - | Stock Option (right to buy) | ||
| Veracyte Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2020 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.60 per share. | 19 Oct 2020 | 10,000 | 10,000 (0%) | 0% | 7.6 | 76,000 | Common Stock |
| Caredx Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 9,745 | 0 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.95 per share. | 21 Sep 2020 | 9,745 | 90,893 (0%) | 0% | 5.0 | 48,238 | Common Stock |
| Caredx Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 6,679 | 0 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.49 per share. | 21 Sep 2020 | 6,679 | 81,148 (0%) | 0% | 5.5 | 36,668 | Common Stock |